| Author, Year | N | Chemotherapy | Gastrectomy Rate | MST (Months) | 1-Year Survival | Most Frequent G3 Toxicity |
| Paclitaxel | ||||||
| Kitayama, 2014 [32] | 64 | IP Paclitaxel + IV Paclitaxel + Oral S-1 | 53% | 26.4 | 82% | NR |
| Yamguchi, 2013 [33] | 35 | IP Paclitaxel + IV Paclitaxel + Oral S-1 | 60% | 17.6 | 77.1% | 34% (Neutropenia) |
| Kitayama, 2012 [34] | 100 | IP Paclitaxel + IV Paclitaxel + Oral S-1 | 52% | 23.6 | 80% | 36% (Neutropenia) |
| Ishigami, 2012 [35] | 40 | IP Paclitaxel + IV Paclitaxel + Oral S-1 | NR | 22.5 | 78% | 38% (Neutropenia) |
| Docetaxel | ||||||
| Canbay, 2014 [36] | 194 | IP Docetaxel + IP Cisplatin + Oral S-1 followed by CRS + HIPEC | 78% | 15.8 | 66% | NR for NIPS |
| Fushida, 2014 [37] | 39 | IP Docetaxel + Oral S-1 | 36% | 16.2 | 70% | 19% (Anorexia) |
| Yonemura, 2012 [29] | 96 | IP Docetaxel + IP Cisplatin + Oral S-1 | 70% | 14.4 (all) 21.1 (CC-0) | 61% (all) | 3.1% (Fatigue) |
| Fujiwara, 2012 [31] | 18 | IP Docetaxel + Oral S-1 | 89% | 24.6 | 76% | 6% (Neutropenia) |
| Yonemura, 2009 [28] | 79 | IP Docetaxel + IP Cisplatin + Oral S-1 | 38% | 20.4 (CRS) | 87.4% (CRS) | 3.8% (Derange Renal Function) |